1. Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: Rationale and options

   • Guido Grassi

   Invited Commentary Pages: 277 - 280

2. Web alert

   News Pages: 281 - 283

3. Literature alert

   Abstract Pages: 284 - 289

4. Clinical Trials Report

   • Helmy M. Siragy

   BriefCommunication Pages: 293 - 294

5. Has the role of calcium channel blockers in treating hypertension finally been defined?

   • George S. Chrysant
   • Steven G. Chrysant

   OriginalPaper Pages: 295 - 300

6. Regression of left ventricular hypertrophy is a key goal of hypertension management

   • Rubin Zhang
   • Judy Crump
   • Efrain Reisin

   OriginalPaper Pages: 301 - 308

7. Management of diabetic and hypertensive cardiovascular disease

   • Edward D. Frohlich
   • James R. Sowers

   OriginalPaper Pages: 309 - 315

8. Clinical Trials Report

   • Michael A. Weber
   • Domenic A. Sica

   BriefCommunication Pages: 319 - 321

9. Lessons from trials in hypertensive type 2 diabetic patients

   • Luis M. Ruilope

   OriginalPaper Pages: 322 - 328

10. Trials in isolated systolic hypertension: An update

    • Bernard Waeber

    OriginalPaper Pages: 329 - 336

11. Renal handling of angiotensin receptor blockers: Clinical relevance

    • Domenic A. Sica

    OriginalPaper Pages: 337 - 339

12. Ongoing trials: What should we expect after ALLHAT?

    • Ji-Guang Wang
    • Jan A. Staessen
    • Anthony M. Heagerty

    OriginalPaper Pages: 340 - 345

13. Recent clinical trials with omapatrilat: New developments

    • Anne Zanchi
    • Marc Maillard
    • Michel Burnier

    OriginalPaper Pages: 346 - 352